Summary
The EMA’s veterinary medicines committee issued positive opinions on five marketing-authorisation applications, including Scovella under the EU limited-market framework. It also adopted a new report on antimicrobial use and resistance in humans and animals.
The European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued positive opinions on five veterinary medicine marketing-authorisation applications at its 3–5 November 2026 meeting. The products cover conditions in horses, dogs and pigs. The committee also adopted a new EU/EEA report on antimicrobial consumption and resistance, which is scheduled for publication on 10 December.
A positive CVMP opinion is a recommendation in the EU authorisation process; the European Commission takes the final decision on a marketing authorisation.
Five positive opinions, including one under a limited-market framework
The opinions cover Scovella (velagliflozin), for reducing hyperinsulinaemia and the associated risk of laminitis in horses with Equine Metabolic Syndrome that have not responded to changes in husbandry and exercise. The opinion followed a re-examination of the committee’s June 2026 opinion. EMA says Scovella is the first veterinary medicine the committee has recommended under the limited-market framework since Regulation (EU) 2019/6 came into effect in 2022. The framework allows tailored documentation requirements and an authorisation based on a favourable benefit-risk assessment for a limited market.
The other positive opinions are for Credelio Quattro, for dogs with mixed external and internal parasite infestations or infections when treatment against ectoparasites, cestodes and nematodes is indicated at the same time; and Laverdia (verdinexor), to increase time to progression in dogs with stage II, III or IV lymphoma when treatment at home is indicated. The committee also recommended Streptoporc, which is intended to protect piglets through active immunisation of pregnant sows and gilts against effects associated with Streptococcus suis genotype 1.1, and Nobivac PLUS DHPPi / Leptos, for active immunisation of dogs from six weeks of age against specified viral and bacterial infections.
CVMP also issued positive opinions on variations to existing products. These include adding ear-mite treatment to Credelio’s indication and adding “aggression” as a very rare adverse event in Zenrelia’s product information. Other variations concerned obligations relating to vaccine potency, immunity or shelf-life evidence. The committee recommended extending by one year the exceptional-circumstances marketing authorisations for the avian influenza vaccines Vaxxinact H5 and Vaxxitek HVT+IBD+H5.
Antimicrobial report adds an environmental perspective
The committee adopted the fifth joint inter-agency report on integrated analysis of antimicrobial-agent consumption and antimicrobial resistance in bacteria from humans and food-producing animals in the EU/EEA, known as JIACRA V. EMA says the analysis incorporates environmental data and expertise from the European Environment Agency, examines post-COVID trends from 2022 to 2024, and presents new long-term evidence that sustained reductions in antimicrobial use are associated with improved bacterial susceptibility at country level.
Bacterial susceptibility describes how responsive bacteria are to antimicrobial agents. The reported country-level association connects patterns of medicine use with changes in that responsiveness; it is not, by itself, a claim that every reduction in use produces the same result in every setting. The report is due to be published on the websites of the European Centre for Disease Prevention and Control, the European Food Safety Authority and EMA on 10 December 2026.